candesartan cilexetil has been researched along with Heart Diseases in 4 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Heart Diseases: Pathological conditions involving the HEART including its structural and functional abnormalities.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this 2×2 factorial, randomized, placebo-controlled, double-blind, single-center trial, patients with early breast cancer were assigned to concomitant treatment with candesartan cilexetil, metoprolol succinate, or matching placebos." | 9.41 | Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. ( Fagerland, MW; Geisler, J; Gravdehaug, B; Gulati, G; Heck, SL; Hoffmann, P; Mecinaj, A; Omland, T; Ree, AH; Røsjø, H; Schulz-Menger, J; Steine, K, 2021) |
| "In this 2×2 factorial, randomized, placebo-controlled, double-blind, single-center trial, patients with early breast cancer were assigned to concomitant treatment with candesartan cilexetil, metoprolol succinate, or matching placebos." | 5.41 | Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. ( Fagerland, MW; Geisler, J; Gravdehaug, B; Gulati, G; Heck, SL; Hoffmann, P; Mecinaj, A; Omland, T; Ree, AH; Røsjø, H; Schulz-Menger, J; Steine, K, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heck, SL | 1 |
| Mecinaj, A | 1 |
| Ree, AH | 1 |
| Hoffmann, P | 1 |
| Schulz-Menger, J | 1 |
| Fagerland, MW | 1 |
| Gravdehaug, B | 1 |
| Røsjø, H | 1 |
| Steine, K | 1 |
| Geisler, J | 1 |
| Gulati, G | 1 |
| Omland, T | 1 |
| Arumugam, S | 1 |
| Thandavarayan, RA | 1 |
| Palaniyandi, SS | 1 |
| Giridharan, VV | 1 |
| Arozal, W | 1 |
| Sari, FR | 1 |
| Soetikno, V | 1 |
| Harima, M | 1 |
| Suzuki, K | 1 |
| Kodama, M | 1 |
| Watanabe, K | 1 |
| Isobe, N | 1 |
| Taniguchi, K | 1 |
| Oshima, S | 1 |
| Ono, Z | 1 |
| Adachi, H | 1 |
| Toyama, T | 1 |
| Naito, S | 1 |
| Hoshizaki, H | 1 |
| Kamiyama, H | 1 |
| Trenkwalder, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: A Randomized, Placebo-controlled, 2x2 Factorial, Double Blind Trial of Candesartan and Metoprolol[NCT01434134] | Phase 2 | 130 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for candesartan cilexetil and Heart Diseases
| Article | Year |
|---|---|
Efficacy and tolerability of candesartan cilexetil in special patient groups.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Heart | 2000 |
1 trial available for candesartan cilexetil and Heart Diseases
| Article | Year |
|---|---|
Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazol | 2021 |
2 other studies available for candesartan cilexetil and Heart Diseases
| Article | Year |
|---|---|
Candesartan cilexetil protects from cardiac myosin induced cardiotoxicity via reduction of endoplasmic reticulum stress and apoptosis in rats: involvement of ACE2-Ang (1-7)-mas axis.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2012 |
Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2002 |